The purpose of this study is to provide 24 - 52 week efficacy, safety and tolerability data, as well as up to 3-year efficacy, safety and tolerability data in subjects with active Psoriatic Arthritis despite current or previous nonsteroidal anti-inflammatory drug (NSAID), disease-modifying antirheumatic drug (DMARD) therapy and/or previous anti-tumor necrosis factor alpha (TNFα) therapy.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01989468?cond=%22Arthritis%22&lup_s=10/31/2013&lup_d=30
